A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis

In this trial involving individuals with anti-CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months.

Authors

Institutions

Publication Details

Journal
Arthritis & Rheumatology
Published
2025-08-30
DOI
https://doi.org/10.1002/art.43366
Citations
12
Primary Topic
Drug-Induced Ocular Toxicity
Type
article
Field-Weighted Citation Impact
20.48

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis

Athan Tiliakos, Elena Schiopu, Diane Horowitz, Kevin D. Deane et al.
12 citations
Arthritis & Rheumatology
Drug-Induced Ocular Toxicity
20.48
article

A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis

Athan Tiliakos, Elena Schiopu, Diane Horowitz, Kevin D. Deane, Maureen McMahon, Ashley Frazer‐Abel, Jeffrey A. Sparks, David A. Fox, Jonathan Kay, Chelsie Fleischer, Cristina Arriens, Joel M. Guthridge, V. Michael Holers, M. Kristen Demoruelle, Christopher C. Striebich, Jonathan Graf, John M. Davis, Kate York, Melissa E. Greenleaf, E. Blair Solow, Elizabeth A. Bemis, Sarah Walker, Lindsy Forbess, Janel Fedler, Marie L. Feser, Maria I. Danila, Ted R. Mikuls, C. Strickland, Judith A. James, Jennifer M. Grossman, James R. O’Dell, Lynette Keyes‐Elstein, M. Byron, Ellen Goldmuntz
article en
12 citations

Abstract

In this trial involving individuals with anti-CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months.

Arthritis & Rheumatology
Cedars-Sinai Medical Center (US), Brigham and Women's Hospital (US), National Institutes of Health (US), Northwell Health (US), Feinstein Institute for Medical Research (US), Mayo Clinic (US), Harvard University (US), Emory University (US), University of California, Los Angeles (US), University of Massachusetts Chan Medical School (US), University of California, San Francisco (US), Augusta University (US), University of Michigan (US), University of California System (US), Oklahoma Medical Research Foundation (US), University of Alabama at Birmingham (US), National Institute of Allergy and Infectious Diseases (US), Mayo Clinic in Florida (US), Rho (United States) (US), Anstalt für Verbrennungskraftmaschinen List (Austria) (AT), University of Colorado Anschutz Medical Campus (US), University of Nebraska Medical Center (US), University of San Francisco (US), The University of Texas Southwestern Medical Center (US)
National Institutes of Health, National Institute of Allergy and Infectious Diseases
Openalex Percentile: Top 0%
Drug-Induced Ocular Toxicity
20.48
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.